Drug
Nemolizumab
Nemolizumab: highest development phase Phase 3, developed by Chugai, Galderma. 9 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Chugai, Galderma
Trials
| Drug | Phase | Indication |
|---|---|---|
| Nemolizumab NCT03989349 | Phase 3 | Moderate-to-Severe Atopic Dermatitis |
| Nemolizumab 30 mg NCT07762833 | Phase 3 | Atopic Dermatitis |
| Nemolizumab NCT03989206 | Phase 3 | Moderate-to-Severe Atopic Dermatitis |
| nemolizumab (CIM331) NCT01986933 | Phase 2 | Atopic Dermatitis |
| Nemolizumab NCT03100344 | Phase 2 | Atopic Dermatitis |
| nemolizumab NCT07074977 | Phase 2 | Chronic Pruritus of Unknown Origin |
| Nemolizumab NCT04921345 | Phase 2 | Moderate-to-Severe Atopic Dermatitis |
| Nemolizumab NCT04365387 | Phase 2 | Dermatitis, Atopic |
| Nemolizumab NCT07660835 | Phase 2 | Moderate-to-Severe Atopic Dermatitis |
Latest
Follow Nemolizumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.